INTRODUCTION
cancer, Cancer
CANCER, CANCER
The ability to effectively treat cancer while maintaining patients' health‐related quality of life (HRQoL) is critically important to maximize therapeutic benefits. Cancer diagnoses impair patients' HRQoL both during and after treatmentIn the SELECT study, lenvatinib 24 mg/day demonstrated superior efficacy compared with placebo in patients with RR‐DTC.Study 211 was designed to determine if a lower starting dose of lenvatinib (18 mg/day) would provide comparable efficacy and an improved safety profile versus the approved starting dose of 24 mg/day in patients with RR‐DTC.Few data exist on HRQoL in patients with RR‐DTC receiving kinase inhibitor therapies. Because real‐world analyses typically include few patients and prospective controlled clinical trial data are lacking, the effect of kinase inhibitor treatment, and lenvatinib specifically, on HRQoL in patients with RR‐DTC is an area that requires additional research.